Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 16/20 | 1.00 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.72 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.61 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.61 |
| ▸ | CKS1B | P61024 | 1/20 | 0.56 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11972974 | 0.88 | SLC40A1 (1.00) | SLC40A1GLO1HSP90AA1HSP90AB1CKS1B | |
| SCHEMBL11995653 | 0.84 | SLC40A1 (0.77) | SLC40A1GLO1HSP90AA1HSP90AB1CKS1B | |
| SCHEMBL30925462 | 0.84 | SLC40A1 (1.00) | SLC40A1GLO1CKS1BSKP2 | |
| SCHEMBL11973652 | 0.84 | SLC40A1 (1.00) | SLC40A1GLO1CKS1BSKP2 | |
| SCHEMBL11995649 | 0.83 | SLC40A1 (1.00) | SLC40A1GLO1CKS1BSKP2 | |
| SCHEMBL11995659 | 0.83 | SLC40A1 (1.00) | SLC40A1GLO1CKS1BSKP2 | |
| SCHEMBL26964258 | 0.82 | SLC40A1 (0.74) | SLC40A1GLO1HSP90AA1HSP90AB1CKS1B | |
| SCHEMBL30553410 | 0.82 | SLC40A1 (0.74) | SLC40A1GLO1HSP90AA1HSP90AB1CKS1B | |
| SCHEMBL11995661 | 0.81 | SLC40A1 (1.00) | SLC40A1GLO1HSP90AA1HSP90AB1CKS1B | |
| SCHEMBL30553454 | 0.79 | SLC40A1 (0.71) | SLC40A1GLO1CKS1BSKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3180328-A1 | QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2017-06-21 | — | — | EP | claimed |
| US-20160068490-A1 | UBIQUITINATION INHIBITORS | MIDCAP FINANCIAL TRUST | 2016-03-10 | — | — | US | claimed |
| WO-2016025779-A1 | QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-18 | — | — | WO | claimed |
| US-10040766-B2 | Ubiquitination inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| EP-3180328-A1 | QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20160068490-A1 | UBIQUITINATION INHIBITORS | MIDCAP FINANCIAL TRUST | 2016-03-10 | — | — | US | disclosed |
| WO-2016025779-A1 | QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| US-9102688-B2 | Sulfonaminoquinoline hepcidin antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-9102688-B2 | Sulfonaminoquinoline hepcidin antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | SLC40A1 2/4885GLO1 3935/4885HSP90AA1 1109/4885 |
| US-20160068490-A1 | UBIQUITINATION INHIBITORS | MDM2, RBX1, NEDD4 | SLC40A1 4627/4885GLO1 278/4885HSP90AA1 2038/4885 |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | SLC40A1 2/4885GLO1 3935/4885HSP90AA1 1109/4885 |
| US-10040766-B2 | Ubiquitination inhibitors | MDM2, RBX1, NEDD4 | SLC40A1 4627/4885GLO1 278/4885HSP90AA1 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.